Ozempic vs Zepbound
Semaglutide vs Tirzepatide — Complete Comparison (2026)
Ozempic (semaglutide) is a GLP-1 injection branded for type 2 diabetes; Zepbound (tirzepatide) is a dual GLP-1/GIP injection branded for obesity. People compare them constantly for weight loss. Here's how their mechanisms, data, and indications actually differ.
Ozempic vs Zepbound: At a Glance
- ✓GLP-1 receptor agonist
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for type 2 diabetes
- ✓Wegovy is the obesity-branded twin (same drug)
- ✓Strong weight loss and HbA1c reduction
- ✓Novo Nordisk
- ✓Dual GLP-1/GIP receptor agonist
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for obesity and sleep apnea
- ✓Mounjaro is the diabetes-branded twin (same drug)
- ✓SURMOUNT-1: ~20.9% weight loss at 72 weeks
- ✓Eli Lilly
Detailed Comparison
| Feature | Ozempic (Semaglutide) | Zepbound (Tirzepatide) |
|---|---|---|
| Generic | Semaglutide | TirzepatideBest |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Brand Indication | Type 2 diabetes | Obesity / sleep apnea |
| Weight-Loss Twin | Wegovy (semaglutide 2.4 mg) | Zepbound is the obesity brand |
| Administration | Once-weekly injection | Once-weekly injection |
| Weight Loss | Strong (semaglutide; ~15% at 2.4 mg) | ~20.9% at 72 weeks |
| Extra Indications | CV risk reduction (in diabetes) | Obstructive sleep apnea |
| Side Effects | Nausea, vomiting, diarrhea | Nausea, diarrhea, constipation |
| FDA Status | Approved (diabetes 2017) | Approved (obesity 2023) |
How to Choose
Maximum Weight Loss
Tirzepatide (Zepbound) generally produces more weight loss than semaglutide thanks to its dual mechanism — about 20.9% at 72 weeks.
On-Label for Weight
Zepbound is FDA-approved for obesity; Ozempic is approved for diabetes. For weight-loss coverage, the obesity brand matters — that's Zepbound or Wegovy.
Diabetes Control
Both lower blood sugar well. If diabetes is the diagnosis, Ozempic is on-label; the tirzepatide diabetes brand is Mounjaro.
Extra Indication
Zepbound carries an obstructive sleep apnea indication. Ozempic has cardiovascular risk-reduction data in diabetes.
Tolerability
Both cause GI side effects during titration. Individual tolerance varies — some do better on one than the other.
Cost & Access
Both are costly without coverage. Indication-driven insurance rules often decide the real-world choice.
Which Should You Choose?
For weight loss, the data favors tirzepatide (Zepbound): its dual GLP-1/GIP mechanism produced roughly 20.9% weight loss at 72 weeks, more than semaglutide achieves. And because Zepbound is FDA-approved for obesity, it is usually the on-label, coverage-relevant option for weight loss — whereas Ozempic is approved for diabetes.
There is an important brand nuance here. Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide). The "weight-loss versions" are Wegovy and Zepbound. Many people end up comparing Ozempic vs Zepbound because Ozempic is the famous name, but for obesity the apples-to-apples comparison is Wegovy vs Zepbound.
If you have diabetes, Ozempic is on-label and effective. If your goal is weight loss, Zepbound has the higher ceiling and the obesity indication. Track your dose, weight, and side effects in Shotlee so you can see your real-world response on whichever you take.
Ozempic vs Zepbound: Frequently Asked Questions
Zepbound (tirzepatide) generally produces more weight loss — about 20.9% at 72 weeks — than semaglutide. It is also FDA-approved for obesity, while Ozempic is approved for diabetes. For weight loss specifically, Zepbound (or Wegovy) is the on-label choice.
Ozempic is semaglutide, a GLP-1 agonist branded for type 2 diabetes. Zepbound is tirzepatide, a dual GLP-1/GIP agonist branded for obesity. Both are once-weekly injections from different companies.
For weight loss, the cleaner comparison is Wegovy vs Zepbound, because those are the obesity-indicated brands. Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide).
For weight loss, yes — a higher weight-loss ceiling and an obesity indication, plus a sleep-apnea indication. Ozempic's strengths are its diabetes track record and cardiovascular data in diabetes.
Yes. Shotlee tracks any GLP-1 — semaglutide and tirzepatide included — with dose logs, weight trends, and side-effect tracking.
Track Ozempic or Zepbound in Shotlee
Free dose logging, weight trends, and side-effect tracking for any GLP-1.
📚References & sources
Latest on Ozempic
Ozempic Muscle Loss: How a New Compound Preserves Strength
New research from Stanford Medicine reveals a potential solution to the muscle loss associated with GLP-1 medications like Ozempic and Wegovy, offering hope for stronger, healthier weight loss.
8 min read
Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat
The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.
7 min read
Wegovy, Mounjaro & Your Libido: How GLP-1s Reshape Desire
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
9 min read